Abstract
To date, calculations of SARS-CoV-2 transmission networks at a population level have not been performed. Networks that estimate infections between individuals and whether this results in a mutation, can evaluate fitness of a mutational clone by how much it expands in number as well as determining the likelihood a transmission results in a new variant.
Transmission networks of SARS-CoV-2 infection between individuals in Australia were estimated for Delta and Omicron variants using a novel method. Many of the sequences were identical, with clone sizes following power law distributions driven by negative binomial probability distributions for both the number of infections per individual and the number of mutations per transmission (mean 1.0 nucleotide change for Delta and 0.79 for Omicron). Using these distributions, an agent based model was able to replicate the observed clonal network structure, providing a basis for more detailed COVID-19 modelling. Recombination events, tracked by insertion/deletion (indel) patterns, occurred for each variant in these outbreaks. The residue at position 142 in the S open reading frame (ORF), frequently changed between G and D for Delta sequences, but this was independent of other mutations. On the other hand, several Omicron mutations were significantly connected across different ORF. This model reveals key transmission characteristics of SARS-CoV-2 and may complement traditional contact tracing and other public health strategies. This methodology can also be applied to other diseases as genetic sequencing of viruses becomes more commonplace.
Author summary As SARS-COV-2 spreads through a community, it can mutate and generate new variants. How likely this is to occur and how much a particular viral clone expands, can indicate mutational probabilities and whether some mutations are fitter than others. By better understanding these aspects, future predictions can more accurately encapsulate possible changes in the epidemic within a community. We have developed a new method for piecing together the individual SARS-COV-2 cases that have been sequenced, to generate the structure of transmissions and mutational clones for an outbreak. While this method can be applied to other virus epidemics given sufficient sequenced data, we apply it to Delta and Omicron outbreaks in Australia. Interestingly, transmissions between individuals frequently do not result in mutations, with some clones growing very large. We characterise the probability that a mutation will occur, and track how these changes lead to sequential mutations in these outbreaks.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was funded by an Australian Research Council Discovery grant (DP180103893), awarded to J.M.M. The Australian Research Council (arc.gov.au) had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The only data used were sequence data that are available from GISAID.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes